Georgina Rizik

Global Biotechnology & Healthcare Executive

Georgina Rizik is a Global Biotechnology and Healthcare Executive with over 25 years of experience across the private, public and non-profit sectors. She is a purpose-driven leader who is passionate about transforming the global approach to the commercialization of innovation in order to drive personalized care and health equity. Throughout a distinguished career,

Georgina has consistently been the architect of impactful innovation, integrating diverse experiences essential for C-Suite and Board effectiveness. Georgina brings extensive global commercialization expertise in oncology and specialty medicine, honed through leadership roles in top pharmaceutical companies such as Roche, Novartis, and Boehringer Ingelheim. She has been instrumental in the success of transformative and blockbuster oncology medications, including Femara®, Gleevec®, Herceptin®, and Avastin®. Notably, Georgina has a proven record of delivering outstanding value, shaping markets, and exceeding KPIs, sales, and P&L targets for products and portfolios ranging from $150M to $1B, at a country and global level.

As Chief Executive Officer of SC1 London Life Sciences Innovation District (anchored by King’s College London), Georgina launched the district, set its vision and strategy, ensured operational excellence, secured partnerships with Big Pharma, and built trans-Atlantic collaborations. Serving on the SC1 Board, she refined her governance skills in strategic oversight, risk management, and alignment with long-term goals. Recognized as a forward-thinking strategist and global thought leader, her work has been profiled on the INSEAD Business School Learning Hub.

In addition, Georgina has made significant impact with ventures and start-ups. As a Global Advisor to early-stage HealthTech and BioTech companies through the Creative Destruction Lab, she has guided 10 ventures, focusing on value proposition, business development, GTM strategy, investor collaborations, and fostering SME and Big Pharma partnerships. She is a Strategic Advisor at VoxCell BioInnovation, a private Biotechnology company in Canada which has received national recognition, along with oversubscribed seed rounds.

Having lived and worked across three continents, Georgina possesses deep knowledge of the Canadian, UK, European, US, and international healthcare systems. With the increasing complexity and challenging market dynamics, Georgina has evolved an integrated skill set in global commercialization, start-up advisory, innovation ecosystem leadership, and learning agility.